Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
As of Jun. 2018, EOM Pharmaceutical Holdings has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
EOM Pharmaceutical Holdings (OTCPK:IMUC) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Jun. 2018, EOM Pharmaceutical Holdings has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
EOM Pharmaceutical Holdings Sloan Ratio % Related Terms
EOM Pharmaceutical Holdings Sloan Ratio % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IMUC vs MNTMD, RTTR, BZYR: Sloan Ratio % Comparison
For the Biotechnology subindustry, EOM Pharmaceutical Holdings's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EOM Pharmaceutical Holdings Sloan Ratio % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, EOM Pharmaceutical Holdings's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where EOM Pharmaceutical Holdings's Sloan Ratio % falls into.
EOM Pharmaceutical Holdings Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
EOM Pharmaceutical Holdings's Net Income for the trailing twelve months (TTM) ended in Jun. 2018 was -3.901 (Sep. 2017 ) + -0.431 (Dec. 2017 ) + -1.025 (Mar. 2018 ) + -0.307 (Jun. 2018 ) = $-5.66 Mil.
EOM Pharmaceutical Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2018 was -2.22 (Sep. 2017 ) + -4.929 (Dec. 2017 ) + -1.603 (Mar. 2018 ) + -2.174 (Jun. 2018 ) = $-10.93 Mil.
EOM Pharmaceutical Holdings's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2018 was 0 (Sep. 2017 ) + 0 (Dec. 2017 ) + 0 (Mar. 2018 ) + 0 (Jun. 2018 ) = $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EOM Pharmaceutical Holdings (IMUC) has a Sloan Ratio % of 0.00% as of Jun. 2018. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on EOM Pharmaceutical Holdings and its competitors.
Is EOM Pharmaceutical Holdings' Sloan Ratio % too high?
EOM Pharmaceutical Holdings' current Sloan Ratio % is 0.00%.
How does EOM Pharmaceutical Holdings' Sloan Ratio % compare to MNTMD and RTTR?
EOM Pharmaceutical Holdings' Sloan Ratio % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Biotechnology company?
A good Sloan Ratio % depends on the Biotechnology industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on EOM Pharmaceutical Holdings and its competitors. EOM Pharmaceutical Holdings's current Sloan Ratio % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EOM Pharmaceutical Holdings stock overvalued right now?
EOM Pharmaceutical Holdings (IMUC) has a current Sloan Ratio % of 0.00%. The current Sloan Ratio % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For EOM Pharmaceutical Holdings (IMUC), the current Sloan Ratio % is 0.00% as of Jun. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
EOM Pharmaceutical Holdings Inc is a clinical-stage biotechnology company that is focused on developing drugs with the potential to transform therapeutic paradigms and improve quality of life in patients suffering from debilitating and sometimes deadly diseases. Its products have been approved in the U.S., rheumatoid arthritis, and inflammatory conditions of the gastrointestinal tract such as Crohn's Disease and Ulcerative Colitis as well as various retina disorders characterized by a breakdown of the blood-retinal barrier such as diabetic retinopathy, Aged related macular degeneration and retinal vein occlusion among others. Its pipeline includes its compound EOM613, an investigational novel dynamically dual-acting immunomodulator.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMUC has been successfully added to your 
